2021
DOI: 10.7897/2230-8407.1211169
|View full text |Cite
|
Sign up to set email alerts
|

Review of Design Approaches and Clinical Progress of Mdm2 Inhibitors

Abstract: Activation of the oncogenes and inhibition of the apoptotic function of the p53 protein is a gateway for the cancer genesis. Interaction of the MDM2 protein with p53 protein is responsible for the inhibition of the p53 function. Inhibiting the p53-MDM2 interaction by drug will lead to the p53 release in the cancer cells. And can restart the apoptosis in the cancer cell. Computational methods successfully used for the design and development of the new, potent MDM2 inhibitors. Researchers and pharma companies us… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 14 publications
0
1
0
Order By: Relevance
“…They showed varying MDM2 inhibition potencies. [18] Nutlin 3, like nutlin 1 and 2, is a stereoactive chemical. Among the enantiomers of nutlin 3, nutlin 3a is 150 times more active than 3b.…”
Section: Mdm2 Inhibitorsmentioning
confidence: 99%
“…They showed varying MDM2 inhibition potencies. [18] Nutlin 3, like nutlin 1 and 2, is a stereoactive chemical. Among the enantiomers of nutlin 3, nutlin 3a is 150 times more active than 3b.…”
Section: Mdm2 Inhibitorsmentioning
confidence: 99%
“…Additional resistance should be suspected if the patient receives only one or two functionally equivalent drugs for a one month or more. 22 For example, pyrazinamide is not considered a good companion drug to prevent resistance. If the patient is tolerating only rifampicin and pyrazinamide (due to isoniazid and ethambutol resistance), stabilization of rifampicin may develop.…”
Section: Development Of Further Resistancementioning
confidence: 99%